Sotatercept: all 35 studies that test it

Page 1 of 1. Open to participants first (9), then studies with results posted, then the rest; newest registration first within each.

• A Clinical Study of Sotatercept (MK-7962) in People With Combined Postcapillary and Precapillary Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction (MK-7962-041)Not yet recruitingNCT07839585Phase 3
• A Study of Sotatercept (MK-7962) in Japanese Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-032)RecruitingNCT07646860Phase 2
• A Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) in India (MK-7962-037)RecruitingNCT07600723Phase 4
• Sota-ES - Sotatercept in Patients With Congenital Heart Disease and Eisenmenger´s SyndromeNot yet recruitingNCT07498803Phase 2
• A Study of Sotatercept for Patients With Eisenmenger Syndrome or Unrepaired Shunt-Associated Pulmonary Arterial Hypertension Resistant to Vasodilator TherapyRecruitingNCT07356778Phase 4
• SIRIUS - Initial Combination Therapy With an Endothelin Receptor Antagonist, a Phosphodiesterase-5 Inhibitor and Sotatercept in Patients With Newly Diagnosed Pulmonary Arterial HypertensionNot yet recruitingNCT07266519Phase 2
• Sotatercept in Pulmonary Arterial HypertensionRecruitingNCT07140484Phase 4
• Right Ventricular Compensation With Sotatercept: A Prospective Single Arm Open Label Phase 4 Study to Evaluate the Effects of Sotatercept on Right Ventricular Function in Pulmonary Arterial Hypertension (RECOMPENSE)RecruitingNCT06658522Phase 4
• Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)RecruitingNCT05587712Phase 2
• A Study of Sotatercept in Japanese Pulmonary Arterial Hypertension (PAH) Participants (MK-7962-020)CompletedNCT05818137Phase 3Results posted
• A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)CompletedNCT04945460Phase 2Results posted
• A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH)CompletedNCT04896008Phase 3Results posted
• Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13)TerminatedNCT04811092Phase 3Results posted
• A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR)CompletedNCT04576988Phase 3Results posted
• A Study of Sotatercept for the Treatment of Pulmonary Arterial HypertensionCompletedNCT03738150Phase 2Results posted
• A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (PAH)CompletedNCT03496207Phase 2Results posted
• A Phase 2 Study of Intravenous or Subcutaneous Dosing of Sotatercept (ACE-011) in Patients With End-Stage Kidney Disease on HemodialysisCompletedNCT01999582Phase 2Results posted
• Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)CompletedNCT01736683Phase 2Results posted
• Study to Determine the Safety and Tolerability of Sotatercept (ACE-011) in Adults With Beta( β)- Thalassemia.TerminatedNCT01571635Phase 2Results posted
• Safety and Efficacy Study of Sotatercept in Adults With Transfusion Dependent Diamond Blackfan AnemiaTerminatedNCT01464164Phase 1/2Results posted
• To Determine Safe and Effective Dose of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Participants With Advanced Non-small Cell Lung CancerTerminatedNCT01284348Phase 2Results posted
• Study to Evaluate Effect of a Single Dose of Sotatercept (ACE-011) on Red Blood Cell Mass and Plasma Volume in Participants With Solid TumorsTerminatedNCT01190644Phase 2Results posted
• A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.CompletedNCT01146574Phase 2Results posted
• Study of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer (MK-7962-012)TerminatedNCT00931606Phase 2Results posted
• A Safety, Tolerability and Efficacy Study of ACE-011 in Patients With Osteolytic Lesions of Multiple MyelomaCompletedNCT00747123Phase 2Results posted
• A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)Active, not recruitingNCT07218029Phase 3
• A Study of Sotatercept (MK-7962) in Healthy Females Administered as a Liquid Formulation in an Autoinjector Versus the Lyophilized Formulation (MK-7962-027)CompletedNCT06930664Phase 1
• A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)Active, not recruitingNCT06925750Phase 2
• A Clinical Study of MK-7962 in Healthy Chinese Participants (MK-7962-021)CompletedNCT06843460Phase 1
• Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)Active, not recruitingNCT06814145Phase 2
• A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)CompletedNCT06664801Phase 2
• Sotatercept on Central Cardiopulmonary Performance and Peripheral Oxygen Transport During Exercise in Pulmonary Arterial HypertensionCompletedNCT06409026Phase 4
• Pulmonary Hypertension: Intensification and Personalisation of Combination RxActive, not recruitingNCT05825417Phase 4
• A Phase IIa Study of Sotatercept on Bone Mass and Turnover in Patients With Multiple MyelomaWithdrawnNCT02230917Phase 2
• Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple MyelomaActive, not recruitingNCT01562405Phase 1

← Sotatercept overview